At Kisbee Therapeutics, we are engineering recombinant lipoproteins to target the core biological systems underlying neurodegenerative diseases. Our work represents a novel approach to address the problem of lipid dysregulation observed across many CNS (central nervous system) diseases.
Genetically Validated Approach to Restore Lipid Homeostasis
A growing body of scientific evidence has linked dysfunctional lipid biology to the onset and severity of neurodegenerative disease.
Human genetics has shown that ineffective lipoprotein function as well as mutations in lipid transport genes are central drivers of neurodegeneration. Failure to properly regulate lipid transport between neurons, astrocytes, and microglia leads to excitotoxicity, impaired debris clearance, protein accumulation, inflammation, and reduced lysosomal function, all hallmarks of many neurodegenerative diseases.
By use of our highly optimized, engineered lipoproteins, also known as Kisbee Discs, we are able to intervene and restore lipid homeostasis – gathering and transporting lipids to where they are needed.
Kisbee is focused on advancing programs where we can use biomarkers to connect relevant biology in genetically defined patient populations to improve our ability to demonstrate efficacy and to further characterize the potential therapeutic benefit of our approach. Alzheimer’s disease, along with several other rare, chronic, and acute neurodegenerative conditions, are in focus for initial therapeutic development efforts.
At Kisbee, we have a shared mission with the patient communities we serve to develop new and impactful therapies. We know this mission is best achieved by working together and by having the patient’s perspective of the diseases we are researching.
To listen, really listen, to the patient communities we serve to understand unmet needs and your lived experience
To be transparent about our work
To actively partner with advocacy organizations globally throughout the drug development process
If you have questions or would like to connect with a member of our patient advocacy team, please contact us at patients@kisbeetx.com
Meet the experts behind our vision
Join us in creating a new class of therapeutics for neurodegenerative disease
Kisbee is developing lipid-based therapeutics for neurodegenerative diseases and CNS injuries by bringing together passionate scientists and drug developers. Our diverse experiences and perspectives enable us to support and challenge one another, fostering care, respect, and collaboration. New ideas and innovation fuel us. Science and data guide us. Novel challenges and opportunities bring out our best. We are passionate and driven, and we aspire to overcome obstacles with creativity and careful risk-taking, striving to make a difference for patients.
We show up, we speak with honesty and deliver what we promise. We are confident in one another’s capabilities, display integrity in all things, and assume best intent knowing that we each keep everyone’s best interests at heart
We embrace our different backgrounds, experiences, and viewpoints to strengthen our fabric and enhance our outcomes. Our interactions are driven by universal compassion, so we act with humility and a willingness to understand everyone’s perspective
We leverage our relentless passion for our patients, our business, and our science by creatively looking at things through a different lens, humbly considering alternatives, and remaining eager to learn
We share what we should, when we should. We trust each other to demonstrate sound discernment and to honor the best interests of the individuals when sharing
We exercise mature judgment so we’re entrusted to think, experiment, and discover for ourselves. We’re not afraid to take informed risks, embrace challenges, and push boundaries in order to grow Kisbee and support patients
We are actively hiring across a range of roles in R&D, HR, Finance, and Operations. To inquire about open roles, please email recruiting@kisbeetx.com
Benjamin F. Cravatt, PhD, is a the Gilula Chair of Chemical Biology and Professor in the Department of Chemistry at The Scripps Research Institute. His research group develops and applies chemical proteomic technologies for protein and drug discovery on a global scale and has particular interest in studying biochemical pathways in the nervous system and cancer. Dr. Cravatt is a co-founder of Activx Biosciences (acquired by Kyorin Pharmaceuticals), Abide Therapeutics (acquired by Lundbeck Pharmaceuticals), and Vividion Therapeutics. His honors include a Searle Scholar Award, the Eli Lilly Award in Biological Chemistry, a Cope Scholar Award, the ASBMB Merck Award, the Royal Society of Chemistry Jeremy Knowles Award, and memberships in the National Academy of Sciences, National Academy of Medicine, and American Academy of Arts and Sciences.
Dr. Cravatt obtained his undergraduate education at Stanford University, receiving a B.S. in the Biological Sciences and a B.A. in History. He then received a PhD from The Scripps Research Institute (TSRI) in 1996, and joined the faculty at TSRI in 1997.
